Literature DB >> 14731128

Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.

Jee-Eun Kim1, Kyu Taek Lee, Jong Kyun Lee, Seung Woon Paik, Jong Chul Rhee, Kyoo Wan Choi.   

Abstract

BACKGROUND AND AIM: Although the prognosis for pancreatic cancer is generally poor, it is well known that the survival rate for resected pancreatic cancer is much higher than that for more conservative treatment. The importance of early detection is emphasized for resection of pancreatic cancer. Measurement of serum carbohydrate antigen (CA) 19-9 has shown satisfactory sensitivity and predictive value in symptomatic patients, but no available data has been found on healthy asymptomatic subjects. Thus, the authors aimed to determine the clinical usefulness of CA 19-9 as a screening tool for pancreatic cancer in asymptomatic subjects.
METHODS: From December 1994 to November 2000, 70 940 asymptomatic persons visiting the Health Promotion Center at the Samsung Medical Center, Seoul, Korea, participated. All subjects underwent abdominal ultrasonography and serum CA 19-9 measurement. The authors analyzed the sensitivity, specificity, and predictive values of CA 19-9 for detecting pancreatic cancer. Also, those subjects who had a serum CA 19-9 level above the cut-off value were followed up using a serial check of CA 19-9, computed tomography, or endoscopic retrograde cholangiopancreatography.
RESULTS: The number of subjects with a level of CA 19-9 above the cutoff of 37 U/mL was 1063 (1.5%), including four cases diagnosed with pancreatic cancer. The prevalence of pancreatic cancer over the age of 30 years is 13.66 per 100 000 population in Korea. Therefore, the sensitivity is 100% and the specificity 98.5%. However, the positive predictive value of CA 19-9 for detecting pancreatic cancer is only 0.9% in the asymptomatic population.
CONCLUSION: Mass screening for pancreatic cancer using CA 19-9 levels in asymptomatic subjects is ineffective because of a very low positive predictive value, despite its high sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14731128     DOI: 10.1111/j.1440-1746.2004.03219.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  106 in total

Review 1.  Review of screening for pancreatic cancer in high risk individuals.

Authors:  Alina Stoita; Ian D Penman; David B Williams
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

3.  Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.

Authors:  Xiaoli Jin; Yulian Wu
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

4.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

5.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

Review 6.  [Pancreatic ductal adenocarcinoma].

Authors:  E Gallmeier; T M Gress
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

Review 7.  Pancreatic cancer and the FAMMM syndrome.

Authors:  Henry T Lynch; Ramon M Fusaro; Jane F Lynch; Randall Brand
Journal:  Fam Cancer       Date:  2007-11-09       Impact factor: 2.375

8.  Pancreatic cancer serum detection using a lectin/glyco-antibody array method.

Authors:  Chen Li; Diane M Simeone; Dean E Brenner; Michelle A Anderson; Kerby A Shedden; Mack T Ruffin; David M Lubman
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

Review 9.  Intensity of follow-up after pancreatic cancer resection.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Ann Surg Oncol       Date:  2013-10-04       Impact factor: 5.344

10.  Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.

Authors:  A Xue; C J Scarlett; L Chung; G Butturini; A Scarpa; R Gandy; S R Wilson; R C Baxter; R C Smith
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.